EveryBaby matters
At Risk

About Preterm Birth Issues

Reference: WHO, Born Too Soon, 2012

  • More than 1 in 10 babies is born too early every year 
  • 125 babies die every hour from preterm birth complication worldwide 
  • 40% of babies born extremely early (< 28 weeks) have chronic lung disease, 25% have visual impairment, and 10% have hearing impairment 
  • The preterm birth rate has been rising in last 30 years 

About EveryBaby

EveryBaby is a patented handheld and mobile device that provides a much more accurate and easier-to-use alternative to transvaginal ultrasound. The product uses pioneering patented technology involving a novel method of impedance spectroscopy to pick up on changes to the composition and structure of cervical tissue when a mother is nearing birth. A clinical trial involving 449 pregnant women demonstrated the diagnostic accuracy of the EveryBaby probe. EveryBaby is a safe and accurate alternative available at a fraction of the cost other diagnostic methods, making it especially transformational for low-income countries where the problem is often most acute. It can be used as a routine test for pregnant women to provide peace of mind and to alert clinicians if they need to take action to safe guard the health of the mother and foetus.

not yet regulatory cleared

Our Values


More than 80% of AUC compared to 66% of current standards


Accessible to all mothers repeatably in real-time


A simple, portable probe with disposable tips

We are committed to providing the greatest peace of mind for pregnant women through accurate, accessible and affordable preterm diagnosis.


1 %


Predictive Accuracy

1 %

1. Transvaginal Ultrasound
2. Fetal Fibronectin Test

Study Results

Predictive Accuracy at 20-22 weeks and at 26-28 weeks gestation

EveryBaby predicted spontaneous PTB before 37 weeks with an AUC of 0.76, compared with an AUC of 0.72 for Transvaginal ultrasound and 0.62 for the Fibronectin test.

For assessment at 26–28 weeks in the high-risk group, EveryBaby's AUC was 0.80, compared with an AUC of 0.66 Transvaginal ultrasound and 0.66 for the Fibronectin test.

Combining all three assessments improved the prediction of spontaneous PTB before 37 weeks with an AUC of 0.79 compared with Transvaginal ultrasound and Fibronectin test alone.

Incorporating a history of spontaneous PTB* into the cervical EIS prediction model improved the accuracy of prediction of spontaneous PTB before 37 weeks with an AUC of 0.83 and before 32 weeks with an AUC of 0.86.

* Defined as previous mid-trimester miscarriage or spontaneous PTB
(14 to < 37 weeks)

20~22 w

Transvaginal Ultrasound
Fetal Fibronectin

AUC (95%)






26~28 W

Transvaginal Ultrasound
Fetal Fibronectin

AUC (95%)






Clinical Study: Assessing the Risk of Spontaneous Premature Birth by Electrical Impedance Spectroscopy of the Cervix” (449 women)




Dr. Chris Winter

Chairman / BOD

  • Capital raising, business strategy and networking for EveryBaby
  • Expert in biomedical industry investment, spinout and commercialization
  • Operated Venture Funds for over 20 years
  • 16 M&As, 4 IPOs, over 1 billion USD exits

Dabriel Choi


  • Oversees the entire value chain of EveryBaby
  • Cross-border expert who has run companies in the UK, Canada, and Korea
  • Various academic and professional background including cognitive decision science, arts, design, and consulting

Dr. Gordon Scarth


  • Lead EveryBaby HW and SW development 
  • 22 years of experience overseeing the whole life-cycle of medical device from development to commercialization with deep understanding in both HW and SW
  • Filed over 50 patents
  • Held VP positions in medical device companies

Dr. Dilly Anumba

Inventor / CAB​

  • Clinical Advisor for EveryBaby
  • Vice Chair of the Academic Board of the Royal College of Obstetricians and Gynecologists
  • Expert physician on preterm birth and fetus with 28 years of experience

David Park


  • Overseas Business Development of EveryBaby
  • 8 years of start-up business development experience in the US, Germany, Belgium, Russia and Japan
  • COO, ID301 & Innovelop


Seun Olarewaju

Quality Manager

  • Preparing EveryBaby’s Quality standard compliances
  • 19 years of experience in biomedical industry as a project manager and RA manager
  • Experience in international collaborations and projects across the US and UK

Sunny Gong

Project Manager

  • Supports development, operations and grants of EveryBaby
  • Vast experience in project management

Dr. Clare Lankester

Clinical Managing Consultant

  • Consult EveryBaby team on setting up clinical infrastructure, personnel and coordination on each site
  • 15 years of biomedical experience in industry and academia
  • Expert in strategy & development programs for med tech start-ups

J. M.

Senior System Engineer

  • Leading EveryBaby’s technical development and system engineering
  • 11 years of experience in medical device development including R&D, preclinical, clinical and regulatory submission
  • Filed 9 patents

M. W.

Senior Software Engineer

  • Developing EveryBaby firmware and software algorithm
  • 7 years of experience in designing, implementing, and writing medical device software and firmware
  • Expert on program languages, HW and SW tools

J. A.

Senior Mechanical Engineer

  • Leading EveryBaby system requirements and engineering
  • Over 20 years of working experience as a mechanical engineer in different industries
  • Experience in various functions including product requirement, design validation and many others

Key Opinion Leader

YJ. K., MD

Professor, Ewha Womans University Hospital

  • Director of Mother and Baby Center & Prevention and Treatment of Preterm Birth Center at Ewha Womans University Mokdong Hospital
  • Board of Directors, PREBIC (Preterm Birth International Collaborative)

YH. K., MD

Professor, Yonsei University Severance Hospital

  • Held various academic chair positions at Korean Society of Perinatology,  Korean Society of Ultrasound in OBGYN and many others
  • “Looking at the pilot study result, EveryBaby looks like an useful modality “(Nov 9th 2019 Korean Society of Maternal Fetal Medicine Symposium)

D. K., MD

(Professor, Hadassah Hebrew University Hospital, Israel)

  • Director, Preterm Birth Prevention Center at Hadassah Hebrew University Hospital, Ein Kerem
  • Specialist in Maternal-Fetal Medicine
  • Signed the letter of interest to be the Israel site PI of EveryBaby clinical trial

N.H., MD

Professor, Dubai Hospital

  • Consultant and Head of Department, OBGYN
  • Maternal Fetal Medicine Fellow at DHA Dubai Hospital

Our World Class Partners​

Government of UK, Dubai

✓ Collaboration for Clinical Trial
✓ Full support for clinical adviser, press release, etc

Global Competition

✓ Awardee of the ‘2020 QuickFire Challenge’
✓ Leverage for device development, access to the market.

Top University Hospitals & HMO (Health Maintenance Organization)​

✓ Work with the biggest hospitals in UK, South Korea, Israel.
✓ Leverage of network of physicians, hospitals

Award - winning


Better together

Let’s start a conversation

Send us a message and we’ll get back to you within 2 business days!

Contact Us

visit us

6 Broadfield Court, Broadfield Way, Sheffield, England, S8 0XF

Our hours

© 2023 Everybaby Limited. All Rights Reserved.